Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, spawning a pandemic. Although the respiratory system is the primary site of infection, several other organs may be affected by coronavirus disease 2019 (COVID-19).

Physicians recommend that patients with diabetes and nonalcoholic fatty liver disease should be routinely monitored for underlying renal dysfunction, rather than just patients with diabetes. Monitoring thyrotropin and thyroid hormone levels may be clinically useful when assessing the risk of developing chronic kidney disease in patients with nonalcoholic fatty liver disease; however, future studies are needed to specifically address the risk of chronic kidney disease in patients with nonalcoholic fatty liver disease and hypothyroidism.

With the growing obesity epidemic and the rise of metabolic dysfunction-associated fatty liver disease/non-alcoholic steatohepatitis, the management of patients with chronic liver disease has become quite complex. Patients with metabolic dysfunction-associated fatty liver disease/non-alcoholic steatohepatitis often have multiple comorbidities, exhibiting various features of the metabolic syndrome, increasing the risk of cardiovascular morbidity and mortality.

Elastography plays a particularly important role in detecting liver fibrosis before the disease becomes serious. When liver fibrosis is treated promptly, the risk of cirrhosis and liver cancer can be prevented.

Non-alcoholic fatty liver disease is becoming increasingly common in the community. It is considered the leading cause of hepatitis and elevated liver enzymes, accounting for about 25% in Asian countries. Non-alcoholic fatty liver disease can lead to complications such as cirrhosis and liver cancer if not treated early.